Key Takeaways
- Steady H1, on track for full year: Consolidated revenue grew 13% YoY to ₹1,014 crore with EBITDA up 13% to ₹197 crore; management reaffirmed its 10–12% EBITDA growth guidance for FY25.
- Xanthine is a tale of two markets: The spot market is "quite brutal" on Chinese dumping, but contracted and pharma segments hold margins intact; the strategy is to shift mix decisively toward regulated pharma.
- CDMO/CMO is lumpy but conviction is high: A few large orders slipped 1–2 quarters on customer inventory management and multi-stage project complexity, pushing some revenue beyond FY25; management remains "fairly confident" of stronger growth next year.
- Capacity build-out anchors the FY27 story: Xanthine expansion to 750 tonnes/month and the Atali greenfield site both commission through FY26, making FY27 the year "where bulk of capacity gets operationalized" and meaningful margins flow.
- What to watch next quarter: Whether the H2 CDMO/CMO delivery surge materializes, the pace of Xanthine regulatory filings, and any stabilization in spot-market pricing.
Xanthine: Market Structure & Margin Strategy
- Three-tier market, one brutal spot: The spot market has deteriorated sharply on excess Chinese capacity and dumping by unregulated players; the pharmaceutical market and large-consumer contract market, where suppliers operate with long-term understanding, remain intact.
- Margins protected by raw-material pass-through: Contracted-market pricing follows a raw material cost model, so even as prices softened, lower input costs preserved margins; the spot market fell more than the contracted market.
- Volume steady despite one muted customer: Production ran at rated capacity during the quarter even though deliveries to one customer were muted; current capacity is fully utilized.
- Regulatory filings unlock the pharma shift: The company plans to file a USFDA DMF and an EUGMP CEP for Xanthine derivatives later this fiscal, with approvals and triggering expected next year; this opens the door to regulated pharma supplies, which can begin in H2 FY25 as qualification takes a couple of quarters.
- Target mix to stabilize margins: Once capacity ramps up, management aims for 20% of overall Xanthine capacity going to regulated pharma and 5–10% to non-regulated pharma, a mix that will stabilize the margin profile and reduce spot-market exposure.
Rashesh Gogri: "The way in which, the strategy that we have is that, how do we go away more from spot and move towards more long term market and regulated market, and which can give us stable margins and we don't have to fight on the spot side."
CDMO/CMO: Delays, Visibility & the H2 Bet
- Two headwinds hit the quarter: Projects extended because multi-step synthesis took more time than planned, and some commercially running products were pushed down 1–2 quarters by customers managing their own inventory; both compressed near-term revenue.
- Revenue is inherently lumpy: The business carries 28 commercial projects but revenue is small because innovators do not produce every year; campaigns follow an alternate-year pattern of validation, then small quantity, then larger quantity in the third campaign; the company is still in the supplier-onboarding cycle.
- 9–12 months of visibility, strong conviction: Management sees project visibility stretching 9–12 months and has "great conviction" the segment will grow; the earlier 25% growth target is still being pushed internally, though a 1–2 month shift can swing the number 5–7% lower.
- Significant H2 deliveries expected: Several high-value orders are scheduled for delivery later this year, though some may extend beyond the current financial year; per an analyst's math, H2 could approach ~₹150 crore, though management declined to confirm an absolute number.
- Inventory build-up is project-driven, not a red flag: Inventory rose significantly because CDMO/CMO projects carry long gestation; a sizable order dispatches in one quarter and inventory can come down sharply then, though multi-stage synthesis will cause fluctuations going forward.
- Margin path runs through more stages: Margins improve as the company performs more synthesis stages and moves nearer to final API manufacturing for CDMO/CMO customers.
- Project potential spans a wide range: A matured product with proper customer service could generate ₹5 crore to ₹25 crore per project.
Rashesh Gogri: "Overall, the number that we had earlier mentioned about the 25% growth, we are pushing our team to get that growth. But however, this shift by one or two months can change that number by 5% to 7% also on the lower side."
Capacity Expansion: The FY27 Heavy Lifting
- Xanthine capacity doubling: Two facilities are being upgraded toward a target of 750 tonnes per month; the first phase gets operationalized faster, with incremental capacity online by end of next fiscal and the entire project complete by Q3 of next financial year; full operationalization takes 2–3 quarters after that.
- Atali greenfield on track for Q4 FY25 commissioning: The site, dedicated to CDMO/CMO and intermediate manufacturing, is progressing well; from today, full operationalization is roughly 24 months away, with the site initially filled with intermediate operations for the generic industry to utilize capacity.
- FY27 is the payoff year: Management was explicit that FY27 will be the year where the bulk of capacity gets operationalized, driving more contribution and meaningful margins from both Xanthine and Atali expansions.
- FY26 growth bridges the gap: Before the big capacity hits, FY26 growth will be driven by product mix improvement, phase one of Xanthine operational in H2 FY26 and utilized, and Atali filled with intermediate operations.
- API debottlenecking adds incremental capacity: The API segment, with expansion completed a couple of years back, is now seeing those capacities utilized; 1–2 lines are being debottlenecked to enhance capacity further.
- Future optionality at Tarapur: The API site has space for brownfield expansion, with management seeing future demand for anti-cancer products and API.
API & Margin Performance
- Standalone margins improved on mix: Gross margin improved to 55% and EBITDA margin from 21% to 23%, driven by a better product mix and increased focus on regulated markets in Q2.
- Regulated and semi-regulated markets drove growth: Customer approvals for general and specialized APIs came through this year, and numbers in regulated and semi-regulated markets improved significantly over last year; non-regulated market profitability is lower, so the focus is on increasing engagement with regulated and semi-regulated customers.
- New product commercialization underway: The API business is seeing new products of customers getting commercialized, supporting overall growth despite pricing pressure.
- Cost initiatives in the pipeline: The company is working on biogas, a more efficient boiler, and a solar power plant to reduce costs in coming quarters.
- USFDA intermediate unit adds flexibility: The semi-commercial production expansion at Vapi is in trial production, bridging the gap between small and medium batch sizes and offering gram-scale to ton-scale capability; cost benefits are expected in H2 FY25.
Regulatory & Customer Milestones
- Brazilian inspection cleared with zero observations: Both the Brazilian inspection authority and visa inspection were completed with zero observations, a clean outcome that supports the regulated-markets push.
- Xanthine regulatory filings planned this fiscal: The company will file a USFDA DMF and an EUGMP CEP application for Xanthine derivatives' pharmaceutical applications later in the current fiscal year.
- Regulated pharma supplies can start quickly: Once capacity is available, supplies to regulated markets can begin in the current half (H2 FY25), as qualification takes only a couple of quarters.
- CDMO/CMO engagement pipeline deepening: The business is seeing more engagement from both existing and new customers, progressing through the typical funnel of engagement, customer visit, RFP, audit, initial ordering, and then commercial supply.
- No single-source dependency: Innovators never have a single source; their supply chain strategy is diversified, so the company is in the process of a supplier-onboarding cycle across multiple customers.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA growth | 10–12% growth in FY25; H1 at ₹197 crore, on track for ~₹230 crore in H2 | FY25 |
| Long-term EBITDA growth | About 15% annual growth | Next year onward |
| Xanthine capacity | Incremental capacity operational; entire project complete by Q3 | End of next fiscal; Q3 next financial year |
| Xanthine regulatory filings | File USFDA DMF and EUGMP CEP | Later in current fiscal |
| Xanthine regulatory approvals | Both approvals and triggering expected | Next year |
| Atali greenfield commissioning | Commissioning expected | Q4 FY25 |
| Atali full operationalization | ~24 months from today | ~FY27 |
| FY27 capacity contribution | Bulk of capacity operationalized, meaningful margins driven | FY27 |
| Xanthine pharma mix target | 20% of capacity to regulated pharma, 5–10% to non-regulated pharma | Once capacity ramped up |
| FY26 guidance | Will provide in Q4 call after budget finalized | Q4 FY25 call |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Consolidated revenue (H1 FY25) | ₹1,014 cr, +13% YoY |
| Consolidated EBITDA from operations (H1 FY25) | ₹197 cr, +13% YoY |
| Consolidated PAT (H1 FY25) | ₹110 cr, +11% YoY |
| Standalone EBITDA margin | 23%, improved from 21% |
| Standalone gross margin | 55% |
| Overall gross margin | 65%, ranging 35% to 65% across segments |
| EBITDA growth guidance (FY25) | 10% to 12%, reaffirmed |
| Long-term annual EBITDA growth outlook | ~15% for next few years |
| API and Intermediate business revenue share | 51% of Q2 turnover |
| API and Intermediate regulated market share | 43% of sub-segment revenue |
| CDMO/CMO revenue share | 3% of Q2 turnover |
| CDMO/CMO revenue (FY24) | ₹167 cr |
| CDMO/CMO revenue (H1 FY25) | ~₹50 cr |
| CDMO/CMO growth guidance (FY25) | ~20%, revised from 25% due to spillover |
| CDMO/CMO active projects | 55 projects with 19 customers; 28 commercial, 27 developmental |
| CDMO/CMO innovator share | 90% of projects with innovators |
| Xanthine plant utilization | Near full capacity in Q2 |
| Xanthine capacity expansion target | 9,000 metric tonnes per annum, from 5,000 |
| Xanthine peak revenue potential at 9,000 tonnes | $100–$150 million |
| Xanthine expansion CAPEX | ₹150 cr, inclusive of land |
| Xanthine global capacity share | 12%–15% of 40,000–50,000 tonnes total |
| Xanthine exports | More than 50% |
| H1 FY25 CAPEX (tangible assets) | ₹170 cr |
| H2 FY25 planned CAPEX | ~₹250 cr |
| Overall CAPEX plan | ₹550–600 cr, unchanged |
| Atali greenfield project commissioning | Q4 FY25 expected; full utilization in ~24 months |